News and Insights
The latest news and insights from Genoa Healthcare.
- 340B
Your questions, answered: 340B manufacturer pricing restrictions
Drug manufacturers began implementing restrictions for 340B pricing in 2020, citing alleged misuse by safety-net providers and explosive growth of the 340B Drug Pricing Program. Since then, restrictions for the...
- Feb 25th, 2025
- Behavioral Health
- Clinical Insights
- Treatment
Currently available and emerging therapy options for treatment-resistant depression
Studies show that 50% of people with major depressive disorder don’t respond adequately to initial antidepressant treatment.1 Additionally, an estimated 30% of people with major depressive disorder (MDD) experience treatment-resistant...
- Feb 24th, 2025
- Art Celebration
- Consumer Stories
- People-first Pharmacy Care
Genoa Art Celebration participant heals through art, helps others after losing daughter to substance use disorder
Content warning: This post discusses mental illness and substance use. Please call the Suicide and Crisis Lifeline at 988, the Substance Abuse and Mental Health Services Administration’s National Helpline at...
- Feb 21st, 2025
- Consumer Stories
- Partnering with Genoa
- People-first Pharmacy Care
Genoa pharmacist turned director reunites with consumer
When Jeannie Barrett, PharmD, transitioned from her role as a pharmacist to director of pharmacy operations for Genoa Healthcare, she wondered if she’d get the chance to see her consumers...
- Feb 20th, 2025
- Clinical Insights
- Treatment
RELEXXII®: 6 things to know about the new FDA-approved treatment for ADHD
Staying on top of new medication options for your consumers living with ADHD can be difficult. Learn more about the new FDA-approved medication RELEXXII®, a long-acting formulation of methylphenidate. 1....
- Feb 11th, 2025
- Partnering with Genoa
- People-first Pharmacy Care
3 reasons to transition your pharmacy to Genoa Healthcare
Having a pharmacy right within your clinic offers a lot of benefits: it can break down barriers to care, improve consumer and provider satisfaction and drive better outcomes for the...
- Feb 1st, 2025
- Behavioral Health
- Clinical Insights
- Treatment
4 things to know about Spravato® (Intranasal esketamine)
On January 21, 2025, the FDA approved Spravato® nasal spray as the first and only monotherapy for adults living with TRD. The new label expansion will offer greater flexibility in...
- Jan 28th, 2025
- Art Celebration
- Consumer Stories
- People-first Pharmacy Care
Genoa’s 2024 Art Celebration: Celebrating the healing power of creativity
“I’ve always expressed myself through my art and learned to use my creativity to inspire others”, says Genoa Healthcare 2024 Art Celebration participant Shanelle G. Genoa’s annual Art Celebration invites...
- Jan 24th, 2025
- Behavioral Health
- Clinical Insights
- Treatment
Esketamine: Latest research offers new hope for adolescents with treatment-resistant depression
Adolescents with treatment-resistant depression (TRD) often struggle with a lack of effective treatment options. While ketamine has been shown to help improve outcomes for adults living with major depressive disorder...
- Jan 24th, 2025
- Behavioral Health
- Clinical Insights
- Partnering with Genoa
CMS reporting now required: 4 ways Genoa can help
By Reena Neumann, PharmD, MBA Since January 1, 2024, the Centers for Medicare & Medicaid Services (CMS) has required that clinics provide outcomes data reporting to secure federal funding through...
- Jan 15th, 2025